Fig 1.
Calculation of standardized ratio of enrollment (SR) for COG subgroups.
Table 1.
Estimated US cancer cases by SEER and observed COG enrollment, 2004–2015.
Table 2.
COG enrollment by major demographic factors, stratified by age, 2004–2015.
Table 3.
COG enrollment by disease type (most prevalent in age group), stratified by age, 2004–2015.
Table 4.
COG enrollment stratified by disease type, age, and race, 2004–2015.
Fig 2.
COG enrollment rates and available trials, 2004–2015.
(A) Available Children’s Oncology Group (COG) trials for newly diagnosed patients by disease, 2004–2015* (B) Rate of COG enrollment by age and year. *Presented data is based upon “Opened for Entry” and “Study Closed” dates on the COG member website. Columns represent number of trials open at any time during that year, overall and in which upper age eligibility ≥ 18-years-old (in parenthesis). a Upper age limit for eligibility likely impacted by patient risk stratification definition and age population affected. b Trials for ≥ 18-year-old patient population limited to ovarian and extragonadal tumor only, upper age eligibility for testicular tumor < 15 years old. Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; NHL, non-Hodgkin lymphoma; ALCL, anaplastic large cell lymphoma; GCT, germ cell tumor; RMS, rhabdomyosarcoma; NRSTS, non-rhabdomyosarcoma soft tissue sarcoma; CNS, central nervous system; ATRT, atypical teratoid rhabdoid tumor; EPN, ependymoma; HGG, high grade glioma; DIPG, diffuse intrinsic pontine glioma; LGG, low grade glioma; MBL, medulloblastoma; PNET, primitive neuroectodermal tumor.